BioAlliance Pharma confirms the dynamics of its core business BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to […]

• A growth strategy focused on orphan oncology products • Promising products in advanced development • Reinforced cash reserves at […]

• Key achievements in the clinical development programs and especially: – Livatag®: Phase III study opened in France in June […]

• Orphan Oncology Products: recruitment of the first patients in Phase III clinical trial with Livatag® in primary liver cancer […]